Drugs / Mirtazapine
Mirtazapine
also known as
REMERON · mirtazapine (Remeron) · REMERON SolTab · 6-azamianserin · Avanza · Merta · Mirataz · Mirtazapin · +10 more
Other / unclassified targets HTR2A, HTR2C via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | REMERON | — | 2002-04-09 | fda.gov ↗ |
| Approved | US (FDA) | REMERON | — | 1996-06-14 | fda.gov ↗ |
Trials 62 · started per year
today
US approved 1996
5
1
5
2
1
1
3
3
3
2
2
3
3
4
3
3
5
6
2
4
1
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06684470 | Dec 2024 → Dec 2026 expected | diarrheal disease, irritable bowel syndrome | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 110 trials · 3 met primary | ||||||
| Phase 1 | NCT05247697 | Oct 2022 → Jul 2024 | insomnia | University of Montreal Hospital Centre (CHUM) | Completed | Met primary |
| Phase 1 | NCT06213948 | Aug 2021 → Dec 2024 | functional gastric disease | Universiti Sains Malaysia | Unknown | No outcome recorded |
| Phase 1 | NCT04614584 | May 2021 → May 2024 | methamphetamine dependence | San Francisco Department of Public Health | Completed | No outcome recorded |
| Phase 1 | NCT02228239 | Sep → Dec 2014 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT00878540 | Sep 2008 → Jul 2010 | — | Max-Planck-Institute of Psychiatry | Completed | No outcome recorded |
| Phase 1 | NCT00108498 | Oct 2003 → Mar 2007 | obstructive sleep apnea syndrome | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 1 | NCT00835575 | Jul → Aug 2003 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 1 | NCT00834197 | Jul → Aug 2003 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 1 | NCT00865384 | Sep 2001 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00865696 | Sep 2001 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05452174 | Jun 2022 → Oct 2023 | hyperemesis gravidarum | Northwestern University | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03921151 | May 2014 → Jan 2019 | cocaine dependence | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 220 trials · 2 missed | ||||||
| Phase 2 | NCT07430046 | Jul 2025 → Jun 2026 overdue | Rett syndrome | University of Trieste | Recruiting | No outcome recorded |
| Phase 2 | NCT06323837 | Jun 2024 → Dec 2026 expected | substance-related disorder | Washington State University | Recruiting | No outcome recorded |
| Phase 2 | NCT06309472 | May 2024 → Apr 2026 overdue | inflammatory bowel disease, major depressive disorder | King's College London | Recruiting | No outcome recorded |
| Phase 2 | NCT05380479 | Jun 2022 → Jan 2023 | eating disorder | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Unknown | No outcome recorded |
| Phase 2 | NCT06530290 | Jun 2022 → Dec 2025 overdue | Parkinson disease, anxiety | Shahid Beheshti University of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT05170919 | Jan 2022 → Dec 2026 expected | anorexia nervosa | Englewood Hospital and Medical Center | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT03283488 | Mar 2019 → Feb 2022 | eating disorder, hypoproteinemia, hypercatabolic | University of Sao Paulo | Completed | No outcome recorded |
| Phase 2 | NCT03785691 | Mar 2019 → Jul 2022 | hyperemesis gravidarum | Nordsjaellands Hospital | Terminated | Mixed Stop: Enrollment |
| Phase 2 | NCT03935685 | Feb 2019 → Dec 2030 expected | brain glioma | University of California, Irvine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02650544 | Dec 2015 → Jun 2018 | depressive disorder, non-small cell lung carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT02458690 | Jul 2015 → Aug 2019 | coronary artery disorder, dysthymic disorder, major depressive disorder, stroke disorder | Indiana University | Completed | Missed primary |
| Phase 2 | NCT01501396 | Sep 2013 → Sep 2015 | eating disorder | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 2 | NCT01165541 | Sep 2010 → Oct 2012 | alcohol dependence | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00832520 | Nov 2008 → Jul 2010 | cancer of unknown primary site | New Mexico Cancer Research Alliance | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00742573 | Aug 2008 → Jan 2014 | major depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2 | NCT00488072 | Jan 2007 → Dec 2027 expected | cancer of unknown primary site, eating disorder, insomnia | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01949571 | Jan 2007 → Jul 2011 | drug-induced mental disorder, substance abuse, substance withdrawal syndrome | National Institute of Psychiatry Ramón de la Fuente Muñiz | Completed | No outcome recorded |
| Phase 2 | NCT00322309 | Sep 2005 → Jul 2009 | cocaine dependence, depressive disorder | Boston University | Completed | Missed primary |
| Phase 2 | NCT00874003 | Apr 2004 → Jul 2006 | alcohol dependence | Sahlgrenska University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00385437 | Apr 2003 → Jun 2004 | depressive disorder, hypersomnia | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT04747314 | Mar 2021 → Nov 2024 | anxiety, chronic pain syndrome | Ajay Wasan, MD, Msc | Completed | No outcome recorded |
| Phase 2/3 | NCT01598584 | Jun 2012 → Dec 2015 | malignant pancreatic neoplasm | Tianjin Medical University Cancer Institute and Hospital | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT00080158 | Mar 2004 → Jun 2007 | depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 36 trials · 1 met primary · 2 missed | ||||||
| Phase 3 | NCT04763135 | Dec 2021 | cancer, metastatic neoplasm | Hospices Civils de Lyon | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03031184 | Jan 2017 → Jun 2020 | dementia | University of Sussex | Completed | Missed primary |
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT02336750 | Dec 2014 → Dec 2021 | breast cancer | Fudan University | Completed | Met primary |
| Phase 3 | NCT02541526 | May 2013 → Jan 2017 | amphetamine abuse, heroin dependence | Universiti Sains Malaysia | Unknown | No outcome recorded |
| Phase 3 | NCT01302964 | Aug 2010 → Oct 2017 | autism spectrum disorder | Massachusetts General Hospital | Completed | Missed primary |
| Phase 412 trials · 2 missed | ||||||
| Phase 4 | NCT05978219 | May → Dec 2023 | major depressive disorder | National Institute of Mental Health, Dhaka | Completed | No outcome recorded |
| Phase 4 | NCT04155008 | Mar → Apr 2021 | cancer-related condition, head and neck cancer, lung cancer, malignant pancreatic neoplasm +1 | Montefiore Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03219008 | Aug 2017 → Dec 2019 | major depressive disorder | Shanghai Mental Health Center | Unknown | Missed primary |
| Phase 4 | NCT02711215 | May 2015 → Jan 2020 | major depressive disorder | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 4 | NCT01916824 | Aug 2013 → Dec 2015 | major depressive disorder | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT01601002 | Jun 2012 → Oct 2015 | major depressive disorder | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 4 | NCT01465919 | Aug 2011 → Dec 2017 | depressive disorder | Seoul National University Boramae Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT02191124 | Jun 2011 → Nov 2012 | major depressive disorder | Capital Medical University | Completed | No outcome recorded |
| Phase 4 | NCT01178671 | Jul 2010 → May 2014 | post-traumatic stress disorder | Research Foundation for Mental Hygiene, Inc. | Completed | Missed primary |
| Phase 4 | NCT00288782 | Feb 2006 → Apr 2007 | depressive disorder | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT00177567 | Jul 2001 → Jan 2004 | bipolar disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00021528 | Jul 2001 → Sep 2006 | major depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT04728581 | Jan 2024 → May 2026 overdue | insomnia, osteoarthritis, knee | St. Anna Ziekenhuis, Geldrop, Netherlands | Not yet recruiting | No outcome recorded |
| — | NCT06681805 | Jan 2023 → Sep 2024 | — | Kafrelsheikh University | Completed | No outcome recorded |
| — | NCT06054321 | Aug 2022 → Dec 2028 expected | major depressive disorder | Chonnam National University Hospital | Recruiting | No outcome recorded |
| — | NCT03148522 | Jun 2017 → Dec 2021 | — | Peking University | Unknown | No outcome recorded |
| — | NCT00600145 | Sep 2007 → Dec 2009 | drug dependence | University of Virginia | Withdrawn | No outcome recorded |
| — | NCT01039740 | Feb 2003 → Dec 2017 | depressive disorder | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT01352572 | Jan 2002 → Dec 2018 | depressive disorder | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT01352559 | Nov 2001 → Mar 2007 | depressive disorder | Samsung Medical Center | Unknown | No outcome recorded |
| Comparator or background therapy43 trials | ||||||
| Phase 0 | NCT06499090 Comparator | Mar 2024 → Dec 2025 | breast cancer | Assiut University | Completed | No outcome recorded |
| Phase 0 | NCT04547842 Comparator | Sep 2020 → Jul 2023 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 0 | NCT01725048 Comparator | Jan 2011 → May 2012 | major depressive disorder, neoplasm | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT04799782 Comparator | Jan 2017 → May 2019 | sleep apnea syndrome, spinal cord injury | Wayne State University | Completed | No outcome recorded |
| Phase 2 | NCT02646449 Comparator | Jun 2015 → Dec 2016 | alcohol-related disorders, major depressive disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 2 | NCT02185131 Comparator | Sep 2013 → Jul 2016 | alcohol-related disorders, major depressive disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 2 | NCT01888835 Comparator | Aug 2013 → Oct 2017 | methamphetamine dependence | Phillip Coffin, MD, MIA | Completed | No outcome recorded |
| Phase 2 | NCT00919295 Comparator | Dec 2008 → Oct 2011 | fibromyalgia | Mahidol University | Completed | No outcome recorded |
| Phase 2 | NCT00497081 Comparator | May 2007 → Mar 2010 | HIV infectious disease, substance abuse | San Francisco Department of Public Health | Completed | No outcome recorded |
| Phase 2 | NCT00249444 Comparator | May 2006 → Dec 2012 | cocaine dependence, depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT03254173 Comparator | Mar 2018 → Oct 2019 | — | Catherine Naseef Hunter | Completed | No outcome recorded |
| Phase 3 | NCT03852160 Background | Dec 2019 → Jul 2021 | major depressive disorder | Janssen-Cilag International NV | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT02400346 Background | Mar 2015 → Jun 2016 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT01867775 Comparator | May 2012 → Dec 2013 | Alzheimer disease, sleep disorder | Brasilia University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT00782405 Comparator | Oct 2008 → Apr 2011 | — | Technical University of Munich | Completed | No outcome recorded |
| Phase 4 | NCT05108688 Comparator | Nov 2021 → Dec 2023 | headache disorder | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT04908605 Comparator | Jun 2021 → Mar 2022 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT04013386 Comparator | Jul → Dec 2019 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT03679052 Comparator | Mar → Aug 2018 | benign shuddering attacks | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT03675555 Comparator | Mar → Aug 2018 | benign shuddering attacks | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT01458626 Comparator | Nov 2012 → Aug 2016 | major depressive disorder | Capital Medical University | Completed | No outcome recorded |
| Phase 4 | NCT01764867 Comparator | Jun 2012 → Oct 2014 | major depressive disorder | Shanghai Mental Health Center | Unknown | No outcome recorded |
| Phase 4 | NCT01109693 Comparator | Dec 2010 → Sep 2015 | major depressive disorder | Kyoto University | Completed | No outcome recorded |
| Phase 4 | NCT01263080 Comparator | Nov 2010 → Dec 2012 | schizophrenia | Capital Medical University | Completed | No outcome recorded |
| Phase 4 | NCT01119924 Comparator | Dec 2009 → Aug 2010 | depressive disorder | Nang Kuang Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT01305707 Comparator | Jul 2009 → Jul 2014 | major depressive disorder | Hospital Universitari de Bellvitge | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00926835 Comparator | May 2009 → May 2015 | major depressive disorder | Ministry of Health & Welfare, Korea | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00590863 Comparator | Mar 2008 → Sep 2009 | major depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 4 | NCT01240096 Comparator | Sep 2006 → Aug 2011 | dyspepsia | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 4 | NCT00302107 Comparator | Apr 2006 → May 2011 | anxiety, post-traumatic stress disorder | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 4 | NCT00150839 Comparator | Mar 2006 → Dec 2009 | major depressive disorder | University of Erlangen-Nürnberg Medical School | Completed | No outcome recorded |
| — | NCT04748523 Comparator | Aug 2018 → Jul 2022 | eating disorder, non-small cell lung carcinoma | National Cancer Institute of Mexico | Completed | No outcome recorded |
| — | NCT02655354 Background | Oct 2015 → Nov 2019 | alcohol-related disorders, brain injury, cognitive impairment with or without cerebellar ataxia, depressive disorder +1 | University of Washington | Completed | No outcome recorded |
| — | NCT01943435 Comparator | Nov 2013 → Jun 2016 | lumbar spinal stenosis | Michael Schneider, DC, PhD | Completed | No outcome recorded |
| — | NCT01944657 Comparator | Sep 2013 → Dec 2015 | major depressive disorder | Sheppard Pratt Health System | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT01896349 Background | Apr 2013 → Aug 2014 | — | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| — | NCT01962753 Background | May 2012 → Jan 2020 | major depressive disorder | University Hospital, Tours | Completed | No outcome recorded |
| — | NCT01488266 Comparator | Nov 2011 → Jan 2013 | major depressive disorder | Korea University | Unknown | No outcome recorded |
| — | NCT00564278 Background | Feb 2008 → Aug 2013 | depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| — | NCT00960830 Comparator | Apr 2007 → Apr 2008 | anxiety, depressive disorder | Universidad Nacional de Rosario | Completed | No outcome recorded |
| — | NCT00817011 Comparator | Apr 2006 → Dec 2016 | depressive disorder | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT01228357 Comparator | Feb 2003 → Dec 2018 | depressive disorder | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT00817375 Comparator | Feb 2003 → Dec 2018 | depressive disorder | Samsung Medical Center | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2018-08-15 | Upsher-Smith Laboratories | Regulatory Sawai Pharmaceutical Receives Approvals for Six Compounds with 13 Strengths of Generic Drugs upsher-smith.com ↗
Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approvals by the Ministry of Health, Labour and Welfare for six compounds with 13 strengths of generic drugs. |
| 2005-06-30 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Final Approval Of Mirtazapine Orally Disintegrating Tablets tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S Food and Drug Administration has granted final approval for the company's ANDA for Mirtazapine Orally Disintegrating Tablets (ODT), 15 mg, 30 mg and 45 mg. |
| 2003-06-19 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Approval of Mirtazapine Tablets, 45 mg tevapharm.com ↗
Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration has approved the company's 45 mg strength of Mirtazapine Tablets. |
| 2003-01-24 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Final Approval of Mirtazapine 15mg, 30mg 180-day Marketing Exclusivity tevapharm.com ↗
Jerusalem, Israel, January 24, 2003 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for the company's Mirtazapine Tablets, 15 mg and 30 mg. |
| 2002-01-16 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Tentative Approval of Mirtazapine 15mg, 30mg and 45mg tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. Food and Drug Administration (FDA) has awarded tentative approval for Mirtazapine tablets, 15 mg, 30 mg and 45 mg. |
All press releases naming this drug 7 releases
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 107 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mirtazapine | “we have restricted the IMPACT list of antidepressants to SSRIs (sertraline, escitalopram, paroxetine, fluoxetine, citalopram), duloxetine, bupropion, and mirtazapine. These...” NCT02458690 ↗105“Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR),...” NCT00564278 ↗ “Citalopram, ecitalopram, fluoxetine, sertraline, paroxetine IR, paroxetine CR, venlafaxine IR, venlafaxine XR (extended release), desvenlafaxine, duloxetine, mirtazapine,...” NCT02400346 ↗ “Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.” NCT00742573 ↗ “Admnistration of 18FAV45 if patient is compliant with one of those treatment: Seroplex, Zoloft, Deroxat, Venlafaxine, Mirtazapine, Moclamine,” NCT01962753 ↗ “Mirtazapine 15mg/day or placebo once a day on the fist week, then 30 mg/day or placebo once a day, and then for 7 consecutive weeks” NCT01119924 ↗ “In case of non-response, after 6 weeks, treatment will be switched to either Mirtazapine, Duloxetine or Venlafaxine” NCT02711215 ↗ “non-SSRI treated group is depressive patients treated with milnacipran, venlafaxine, nortriptyline, or mirtazapine” NCT00817375 ↗ “Adjunctive antidepressant agents: nortriptyline, duloxetine, sertraline, trazodone, or mirtazapine” NCT01943435 ↗ “AD: aripiprazole, bupropion, duloxetine, escitalopram, mirtazapine, sertraline, venlafaxine” NCT04747314 ↗ “mirtazapine_Avanza, Zispin, Remeron” NCT01352572 ↗ |
| Known as | 6-azamianserin | ChEMBL registry synonym — accepted as the source's own label CHEMBL654 ↗ |
| Known as | Avanza | “mirtazapine_Avanza, Zispin, Remeron” NCT00817011 ↗ |
| Known as | Merta | “The M (Mirtazapine) (Merta) group:(n=100)” NCT03675555 ↗ |
| Known as | Mirataz | ChEMBL registry synonym — accepted as the source's own label CHEMBL654 ↗ |
| Known as | Mirtazapin | ChEMBL registry synonym — accepted as the source's own label CHEMBL654 ↗ |
| Known as | Mirtazapina | ChEMBL registry synonym — accepted as the source's own label CHEMBL654 ↗ |
| Known as | mirtazapine (Remeron) | “mirtazapine (Remeron)” NCT01165541 ↗1“Mirtazapine, Remeron” NCT01916824 ↗ |
| Known as | Mirtazapine anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL654 ↗ |
| Known as | mirtazapine is Remergon | “mirtazapine is Remergon” NCT01240096 ↗ |
| Known as | MTZ | “mirtazapine (MTZ) was investigated, a noradrenergic and specific serotonergic antidepressant (NaSSA) for its potential benefits in RTT.” NCT07430046 ↗ |
| Known as | MZP | “This project will evaluate the ability of Mirtazapine (MZP), a pharmacologically unique medication with a growing body of evidence to support its efficacy and safety for the...” NCT06323837 ↗ |
| Known as | Norset | ChEMBL registry synonym — accepted as the source's own label CHEMBL654 ↗ |
| Known as | ORG 3770 | ChEMBL registry synonym — accepted as the source's own label CHEMBL654 ↗ |
| Known as | Promyrtil | ChEMBL registry synonym — accepted as the source's own label CHEMBL654 ↗ |
| Known as | REMERON | “Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR),...” NCT00564278 ↗9“the antidepressant mirtazapine (Remeron) in patients who have been prescribed this medication for major depressive disorder and sleep disruption.” NCT00385437 ↗ “Oral mirtazapine ( REMERON , RD , 30 mg tablets , Organon ) will be the original FDA approved drugs that will be used in the study.” NCT03254173 ↗ “Mirtazapine, sold under the brand name Remeron, is an atypical antidepressant, and as such is used primarily to treat depression.” NCT05452174 ↗ “the clinically effective antidepressant drug mirtazapine (Remeron®)” NCT00288782 ↗ “Mirtazapine (REMERON, Schering-Plough-Organon)” NCT01949571 ↗ “15 mg REMERON® Tablets by Organon Inc.” NCT00865696 ↗ “mirtazapine_Avanza, Zispin, Remeron” NCT00817011 ↗ “mirtazapine (Remeron and others)” NCT01944657 ↗ “Mirtazapine (Remeron)” NCT03935685 ↗ |
| Known as | REMERON SolTab | “15 mg REMERON SolTab® Orally Disintegrating Tablets manufactured for Organon Inc. by CIMA Labs Inc.” NCT00835575 ↗1“Mirtazapine * Commercial name: Remeron® SolTab” NCT06213948 ↗ |
| Known as | Rexer | ChEMBL registry synonym — accepted as the source's own label CHEMBL654 ↗ |
| Known as | Zispin | “mirtazapine_Avanza, Zispin, Remeron” NCT00817011 ↗ |
| Action | Inhibit | “Mirtazapine works through serotinergic (5-HT) mechanisms 5HT 2 and 3, alpha 2 and H1 antagonist and has been noted to decrease excitatory responses in methamphetamine...” NCT00600145 ↗2“Serotonin 2c (5-HT2c) receptor antagonist” CHEMBL654 ↗ “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL654 ↗ |
| Modality | Other / unclassified | “a tetracyclic antidepressant” PMID 33084254 ↗ Oct 2020 |
| Route | Oral | “15 mg by mouth (PO) daily x 15 days; Day 22-29, increased to 30 mg PO daily.” NCT00488072 ↗ |
| Target | HTR2A | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL654 ↗ |
| Target | HTR2C | “Serotonin 2c (5-HT2c) receptor antagonist” CHEMBL654 ↗ |